Swiss cannabis study halted for purity concerns

by Duncan Fisher

September 15, 2022 - 2 min read

The Swiss city of Basel has put a hold on the launch of ‘Weed Care’, Europe’s first recreational cannabis trial, due to concerns over product ‘quality standards’. Source cannabis analysis has found0.1-0.2 parts per million of fluopyram, a pesticide not certified for organic cultivation. ‘Organic’ was part of the legal stipulation for the study’s approval. This production protocol subjects the purity of the harvested cannabis to environmental variables, like soil contaminants, and pesticide residue. Lino Cereghetti, chief operating officer of Pure Production AG, supplier of the source cannabis, suggests that there may be reasonable warrant for review of the experimental statute governing this study. The quantity of fluopyram found in the assay are well within the acceptable range for ordinary produce. Part of the function of pilot studies like this, he observes, besides establishing real-world benefits data, is to judge to what degree studies in general may be over-regulated. 

The problem of purity, and its sibling problem, consistency, are unavoidable in agriculture-based production. Industrial assembly of cannabinoids by synthetic means bypasses this. Using non-cannabis source material obviates any need for testing for THC content in pharmaceutical or practitioner-grade products as well. If THC is required in a product, as in the case of the Weed Care study, this too can be managed without a cannabis precursor, and the amounts can be assured with precision. These techniques are fully scalable, moreover, and do not rely on harvesters’ success with yearly crop yields. 

DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome. 

Cannabigerol (CBG): Another promising cannabinoid?

Cannabigerol (CBG): Another promising cannabinoid?

For some good reasons, research and commercial attention is beginning to turn to cannabigerol, or 'CBG'. 
Read More

October 04, 2022 2 min read

Up close: Cannabinoids in Huntington's chorea

Up close: Cannabinoids in Huntington's chorea

In vitro and in vivo models of Huntington's disease, an inherited condition in which nerve cells in the brain break down over time, show disease-related alterations in the endocannabinoid system, part of the body’s neural cell-signaling network, and the dopamine regulatory system downstream. 
Read More

October 03, 2022 3 min read

Up close: Cannabinoids in neurodegenerative diseases

Up close: Cannabinoids in neurodegenerative diseases

Modulation of cannabinoid receptor signaling should represent a viable therapeutic target in neurodegenerative diseases. 
Read More

September 30, 2022 2 min read

Follow us on Instagram

Net Orders Checkout

Item Price Qty Total
Subtotal $ 0.00

Shipping Address

Shipping Methods